Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
NovaBay Pharma ( (NBY) ) has shared an announcement.
NovaBay Pharmaceuticals announced a significant strategic shift following the sale of its eyecare products. On August 19, 2025, the company entered into a $6 million securities purchase agreement with investor David E. Lazar, who was appointed as the new CEO. This move, which includes issuing non-voting convertible preferred stock, is aimed at maintaining NovaBay’s public listing and exploring strategic investment opportunities, rather than pursuing liquidation. The transaction is expected to provide funds for future acquisitions and a special cash dividend for stockholders, marking a new direction for the company.
The most recent analyst rating on (NBY) stock is a Hold with a $0.50 price target. To see the full list of analyst forecasts on NovaBay Pharma stock, see the NBY Stock Forecast page.
Spark’s Take on NBY Stock
According to Spark, TipRanks’ AI Analyst, NBY is a Neutral.
NovaBay Pharma’s overall stock score is primarily impacted by its poor financial performance, characterized by declining revenues, negative profit margins, and liquidity issues. The technical analysis suggests a lack of strong momentum, with potential oversold conditions. The valuation is weak due to a negative P/E ratio and no dividend yield, reflecting financial distress. These factors collectively result in a low overall stock score.
To see Spark’s full report on NBY stock, click here.
More about NovaBay Pharma
NovaBay Pharmaceuticals, Inc. operates in the pharmaceutical industry, focusing on developing and marketing medical products. The company was previously involved in the eyecare sector with products sold under the Avenova brand.
Average Trading Volume: 36,615
Technical Sentiment Signal: Sell
Current Market Cap: $3.6M
Find detailed analytics on NBY stock on TipRanks’ Stock Analysis page.